PepGel enters joint venture with Enso Discoveries to form PG Biotech LLC
PepGel has formed a joint-venture company PG-Biotech with Enso Discoveries, LLC. PG-Biotech is a pre-clinical and clinical product company focused on delivering the novel capabilities of PepGel and its hybrids to the life science and medical industries. The company was formed in 2017 as a result of Enso Discoveries, LLC and PepGel, LLC joining forces to better deliver high level novel biotechnologies to the world. PG Biotech develops enabling translational biotechnologies and medical devices utilizing PepGel platform technology to improve human and animal health specialized in regenerative medicine, cell therapy, wound healing, sustained release agents, and high throughput drug screening services. Commercialization of this advanced PepGel is intended to address unmet needs to advance cell therapy, life science, and downstream medical applications. Our products and technical service can potentially add a significant benefit and cost impact to customers.